Change of International Restless Legs Syndrome Study Group Rating Scale subscales with treatment and placebo: a pilot study
Ulrike H Mitchell,1 Sterling C Hilton2
1Brigham Young University, Department of Exercise Sciences, 2Department of Educational Leadership and Foundations, Provo, UT, USA
Background: In 2003, the 10-question International Restless Legs Syndrome Study Group Rating Scale (IRLS) was developed as a means of assessing the severity of restless legs syndrome. Two subscales were identified: symptom severity (SS 1) and symptom impact (SS 2). Only one study has investigated the subscales' responsiveness to a 12-week treatment with ropinirole. This current study was undertaken to assess the impact of a 4-week, non-pharmaceutical treatment on the two subscales and to explore whether or not both subscales were impacted by the observed placebo effect.
Methods: The pooled data from questionnaires of 58 patients (41 from both treatment groups and 17 from the sham treatment control group), who participated in two clinical studies, were reviewed. Their change in score over a 4-week trial was computed. The average change in both subscales in both groups was computed and t-tests were performed.
Results: In the treatment group, the average scores of both subscales changed significantly from baseline to week 4 (P<0.005 for both). Compared to the control, SS 1 changed (P<0.001), but not SS 2 (P=0.18). In the sham treatment group, the scores for SS 1 changed significantly (P=0.002), but not for SS 2 (P=0.2).
Conclusion: This study corroborated findings from an earlier study in which both subscales changed with a 12-week drug treatment. It also showed that the observed placebo effect is attributed to a small but significant change in symptom severity, but not symptom impact.
Keywords: restless legs syndrome, RLS severity scale, IRLS subscales, symptom impact, symptom severity
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]